Keymed Makes Hong Kong Debut, Raises $378 million

105
11
Favorite

Keymed Makes Hong Kong Debut, Raises $378 million

Investing.com2021-07-08

Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process. Keymed’s Hong Kong shares were at HK$70 by...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

105

Report

Comment（11）

acyilin
·2021-07-08
nice!
Reply
Like
Report
sohadeline
·2021-07-08
like can comment pls
Reply
Like
Report
Yumiko88
·2021-07-08
Like and comment
Reply
3
Report
Fold Replies
- sohadeline:
  like
  2021-07-08
  Reply
  Report
Suet79
·2021-07-08
G
Reply
1
Report
UpUpUpUpUp
·2021-07-08
Wow!!
Reply
2
Report
alaric
·2021-07-08
Ususus
Reply
1
Report
Fold Replies
- Andylow86:
  Like and comment
  2021-07-08
  Reply
  Report
lizzy04
·2021-07-08
Haha
Reply
3
Report
MrNewman
·2021-07-08
Nice!
Reply
2
Report
Fold Replies
- lizzy04:
  yep
  2021-07-08
  Reply
  Report
cgjy
·2021-07-08
[Miser]
Reply
Like
Report
Jarvis92
·2021-07-08
Like n comment pls
Reply
8
Report
Fold Replies
- nonwoke:
  okay
  2021-07-08
  Reply
  Report
- miaomee:
  Like and comment pls
  2021-07-08
  Reply
  Report
- EriViL:
  Like pla
  2021-07-08
  Reply
  Report
View more 1 comments
JustinMay
·2021-07-08
Cool!
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1169240809?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-08 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169240809","market":"hk","top_or_hot":-1,"title":"Keymed Makes Hong Kong Debut, Raises $378 million","media":"Investing.com","content":"<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Source Link</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","article_id":"1169240809","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","pubTimestamp":1625748735,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"Keymed首次香港上市，融资3.78亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9},"content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":143980829,"gmtCreate":1625755512261,"gmtModify":1703747991752,"author":{"id":"3579911378800254","authorId":"3579911378800254","name":"acyilin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3579911378800254","idStr":"3579911378800254"},"htmlText":"nice!","listText":"nice!","text":"nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143980829","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":143913360,"gmtCreate":1625755139350,"gmtModify":1703747980555,"author":{"id":"3581890280369523","authorId":"3581890280369523","name":"sohadeline","avatar":"https://static.tigerbbs.com/19da53f7b9a8ff8d0b015c5f5adc0982","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581890280369523","idStr":"3581890280369523"},"htmlText":"like can comment pls","listText":"like can comment pls","text":"like can comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143913360","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":143042294,"gmtCreate":1625753695718,"gmtModify":1703747915729,"author":{"id":"4087355322223700","authorId":"4087355322223700","name":"Yumiko88","avatar":"https://static.tigerbbs.com/8de4f8ae37c793c2349956a9b50920f9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087355322223700","idStr":"4087355322223700"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/143042294","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5162865,"gmtCreate":1625755150325,"gmtModify":1635234033756,"authorId":3581890280369523,"author":{"id":3581890280369523,"idStr":"3581890280369523","authorId":3581890280369523,"name":"sohadeline","avatar":"https://static.tigerbbs.com/19da53f7b9a8ff8d0b015c5f5adc0982","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":143042294,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"}],"langContent":"EN"},{"id":143022271,"gmtCreate":1625753182593,"gmtModify":1703747886930,"author":{"id":"3583389578129719","authorId":"3583389578129719","name":"Suet79","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3583389578129719","idStr":"3583389578129719"},"htmlText":"G","listText":"G","text":"G","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143022271","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":143038158,"gmtCreate":1625752051174,"gmtModify":1703747826134,"author":{"id":"3575517733011286","authorId":"3575517733011286","name":"UpUpUpUpUp","avatar":"https://static.tigerbbs.com/f92e5e26e6e720eda3643248da3c21eb","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575517733011286","idStr":"3575517733011286"},"htmlText":"Wow!!","listText":"Wow!!","text":"Wow!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143038158","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149740884,"gmtCreate":1625750629248,"gmtModify":1703747762112,"author":{"id":"3575165357870175","authorId":"3575165357870175","name":"alaric","avatar":"https://static.tigerbbs.com/b25fc239065aa81f222fd3662c8d2d99","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575165357870175","idStr":"3575165357870175"},"htmlText":"Ususus","listText":"Ususus","text":"Ususus","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/149740884","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5161652,"gmtCreate":1625750711196,"gmtModify":1663230709644,"authorId":3583411958858523,"author":{"id":3583411958858523,"idStr":"3583411958858523","authorId":3583411958858523,"name":"Andylow86","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149740884,"type":1,"supId":0,"prevId":0,"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"langContent":"EN"},{"id":149753823,"gmtCreate":1625750279762,"gmtModify":1703747750397,"author":{"id":"3582761710994135","authorId":"3582761710994135","name":"lizzy04","avatar":"https://community-static.tradeup.com/news/529a324eeb69425faecfa95496b40729","vip":1,"crmLevel":9,"crmLevelSwitch":1,"authorIdStr":"3582761710994135","idStr":"3582761710994135"},"htmlText":"Haha","listText":"Haha","text":"Haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149753823","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149725780,"gmtCreate":1625750038140,"gmtModify":1703747744370,"author":{"id":"3575971055509237","authorId":"3575971055509237","name":"MrNewman","avatar":"https://static.tigerbbs.com/530fe22e84a93f106f3c10b865f30180","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575971055509237","idStr":"3575971055509237"},"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/149725780","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5161588,"gmtCreate":1625750271177,"gmtModify":1663230710637,"authorId":3582761710994135,"author":{"id":3582761710994135,"idStr":"3582761710994135","authorId":3582761710994135,"name":"lizzy04","avatar":"https://community-static.tradeup.com/news/529a324eeb69425faecfa95496b40729","vip":1,"crmLevel":9,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149725780,"type":1,"supId":0,"prevId":0,"content":"yep","text":"yep","html":"yep"}],"langContent":"EN"},{"id":149723721,"gmtCreate":1625749782163,"gmtModify":1703747737034,"author":{"id":"3581498631806671","authorId":"3581498631806671","name":"cgjy","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581498631806671","idStr":"3581498631806671"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149723721","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":149788377,"gmtCreate":1625748848599,"gmtModify":1703747709624,"author":{"id":"4087992674383480","authorId":"4087992674383480","name":"Jarvis92","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087992674383480","idStr":"4087992674383480"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/149788377","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5161398,"gmtCreate":1625749055343,"gmtModify":1663230712647,"authorId":3563442467729531,"author":{"id":3563442467729531,"idStr":"3563442467729531","authorId":3563442467729531,"name":"nonwoke","avatar":"https://static.tigerbbs.com/73e577625d645cfa3ebb543fecfcb19a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":5161386,"prevId":0,"content":"<u>okay</u>","text":"<u>okay</u>","html":"<u>okay</u>"},{"id":5161609,"gmtCreate":1625750429040,"gmtModify":1663230709631,"authorId":3569375896365334,"author":{"id":3569375896365334,"idStr":"3569375896365334","authorId":3569375896365334,"name":"miaomee","avatar":"https://static.tigerbbs.com/fd309d5a46384576888494b61b0e5953","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":5161395,"prevId":0,"content":"Like and comment <u>pls</u>","text":"Like and comment <u>pls</u>","html":"Like and comment <u>pls</u>"},{"id":5161395,"gmtCreate":1625749043111,"gmtModify":1663230709129,"authorId":3577087216911488,"author":{"id":3577087216911488,"idStr":"3577087216911488","authorId":3577087216911488,"name":"EriViL","avatar":"https://static.tigerbbs.com/f37d027290c1cdf3fa6cdba6443077c6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":0,"prevId":0,"content":"Like pla","text":"Like pla","html":"Like pla"},{"id":5161386,"gmtCreate":1625748956872,"gmtModify":1635234137992,"authorId":3567656189229002,"author":{"id":3567656189229002,"idStr":"3567656189229002","authorId":3567656189229002,"name":"猫山王77","avatar":"https://static.tigerbbs.com/b0f449741d66eb9e2e9d062335702513","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":149788377,"type":1,"supId":0,"prevId":0,"content":"Done. Like n comment back pls. ?","text":"Done. Like n comment back pls. ?","html":"Done. Like n comment back pls. ?"}],"langContent":"EN"},{"id":149781184,"gmtCreate":1625748819648,"gmtModify":1703747708164,"author":{"id":"3581997079623763","authorId":"3581997079623763","name":"JustinMay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581997079623763","idStr":"3581997079623763"},"htmlText":"Cool!","listText":"Cool!","text":"Cool!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/149781184","repostId":1169240809,"repostType":4,"repost":{"id":"1169240809","kind":"news","pubTimestamp":1625748735,"share":"https://ttm.financial/m/news/1169240809?lang=&edition=fundamental","pubTime":"2021-07-08 20:52","market":"hk","language":"en","title":"Keymed Makes Hong Kong Debut, Raises $378 million","url":"https://stock-news.laohu8.com/highlight/detail?id=1169240809","media":"Investing.com","summary":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and","content":"<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.</p>\n<p>Keymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.</p>\n<p>Of the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.</p>\n<p>The list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.</p>\n<p>Founded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.</p>\n<p>However, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&amp;D investments and administrative expenses increased.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Makes Hong Kong Debut, Raises $378 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Makes Hong Kong Debut, Raises $378 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-08 20:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html><strong>Investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by...</p>\n\n<a href=\"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02162":"康诺亚-B"},"source_url":"https://finance.yahoo.com/news/keymed-makes-hong-kong-debut-013433823.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169240809","content_text":"Investing.com – Keymed Biosciences Inc. (HK:2162) made its debut on the Hong Kong Stock Exchange and raised HK$2.94 billion ($378.48 million) in the process.\nKeymed’s Hong Kong shares were at HK$70 by 1:32 AM ET (5:32 AM GMT), after opening 46.3% higher at $78. The company offered 58.26 million shares priced at HK$53.3 each, the top end of its range of HK$50.5 to HK$53.3.\nOf the more than 20 companies that launched share sales at the end of June 2021, Keymed was one of the most subscribed candidates. Retail investors placed HK$53.2 billion worth of orders, a 171-times oversubscription, for the company’s shares. A total of 15 cornerstone investors also subscribed to HK$1.48 billion worth of shares, or around 50% of the total issued amount.\nThe list of investors includes Invesco, UBS Asset Management, Temasek, Hillhouse Capital, Lake Bleu Capital and CSPC Pharmaceutical. The company was also reportedly able to close the institutional books a day earlier than expected.\nFounded in 2016, Chengdu, China-based Keymed develops therapies to treat cancer and autoimmune diseases. It has nine drug candidates that have been approved as investigational new drugs and is running clinical trials for five of them.\nHowever, with none of the candidates expected to be commercialized before 2023, Keymed has yet to generate profit from product sales. The company’s net loss widened by 3.89 times to CNY818.8 million ($126.49 million) in 2020 as R&D investments and administrative expenses increased.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":105,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}